Iveric Bio (ISEE) PT Raised to $30 at Cowen; Zimura Has Solid Profile in Likely $4B+ Market
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy
September 6, 2022 6:00 AM EDT- Primary Endpoint Met with 14.3% Reduction (p-value = 0.0064) in Mean Rate of Growth (Slope) in GA Area Over 12 Months Using Square Root Transformation; 17.7% Reduction (p-value = 0.0039) Using Observed GA Area -
- Statistically Significant Result with Favorable Safety Profile -
- Post-hoc Analysis of U.S. Patients: 25.5% Reduction (p-value = 0.0037) Using Square Root Transformation; 32.0% Reduction (p-value = 0.0033) Using Observed GA Area -
- Plan to Submit New Drug Application to the FDA by the End of the First Quarter 2023 -
-... More
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 2, 2022 8:00 AM EDTPARSIPPANY, N.J.--(BUSINESS WIRE)-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on September 1, 2022, the Company granted equity-based awards pursuant to the Companys 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees. These inducement grants were approved by the Companys compensation and talent strategy committee pursuant to a... More
